DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,036 filers reported holding DANAHER CORPORATION in Q4 2015. The put-call ratio across all filers is 0.70 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $192,447,763 | +21.2% | 725,424 | +10.6% | 0.07% | +20.0% |
Q2 2023 | $158,752,161 | -12.7% | 656,190 | -3.6% | 0.06% | -30.4% |
Q4 2022 | $181,769,401 | +31.0% | 680,784 | +30.0% | 0.08% | +31.7% |
Q3 2022 | $138,775,000 | +0.5% | 523,737 | -2.8% | 0.06% | -6.2% |
Q2 2022 | $138,080,000 | -7.8% | 538,842 | +7.0% | 0.06% | -12.3% |
Q1 2022 | $149,813,000 | -25.9% | 503,769 | -18.0% | 0.07% | -31.8% |
Q4 2021 | $202,058,000 | -15.8% | 614,628 | -21.4% | 0.11% | -2.7% |
Q3 2021 | $239,980,000 | -11.3% | 781,642 | -21.7% | 0.11% | -18.5% |
Q2 2021 | $270,600,000 | +106.2% | 998,261 | +74.9% | 0.14% | +58.8% |
Q1 2021 | $131,205,000 | -33.1% | 570,609 | -29.0% | 0.08% | -34.6% |
Q4 2020 | $196,157,000 | +21.7% | 803,530 | +8.8% | 0.13% | -3.0% |
Q3 2020 | $161,173,000 | +18.5% | 738,515 | +0.7% | 0.13% | +8.1% |
Q2 2020 | $136,015,000 | +88.2% | 733,346 | +38.4% | 0.12% | +49.4% |
Q1 2020 | $72,287,000 | -32.6% | 529,840 | -24.2% | 0.08% | +2.5% |
Q4 2019 | $107,247,000 | +19.6% | 698,766 | +12.6% | 0.08% | +5.2% |
Q3 2019 | $89,638,000 | +7.1% | 620,625 | +6.0% | 0.08% | +10.0% |
Q2 2019 | $83,703,000 | +24.4% | 585,667 | +14.9% | 0.07% | +20.7% |
Q1 2019 | $67,278,000 | +29.7% | 509,596 | +1.3% | 0.06% | +18.4% |
Q4 2018 | $51,861,000 | -55.4% | 502,913 | -53.0% | 0.05% | -46.2% |
Q3 2018 | $116,195,000 | +134.9% | 1,069,328 | +113.3% | 0.09% | +122.0% |
Q2 2018 | $49,472,000 | -44.2% | 501,338 | -44.7% | 0.04% | -48.1% |
Q1 2018 | $88,734,000 | +10.7% | 906,270 | +5.0% | 0.08% | +12.9% |
Q4 2017 | $80,148,000 | +89.6% | 863,468 | +75.3% | 0.07% | +79.5% |
Q3 2017 | $42,263,000 | -22.6% | 492,701 | -23.8% | 0.04% | -25.0% |
Q2 2017 | $54,594,000 | +14.0% | 646,912 | +15.5% | 0.05% | +15.6% |
Q1 2017 | $47,887,000 | +24.4% | 559,878 | +13.7% | 0.04% | +12.5% |
Q4 2016 | $38,502,000 | -19.4% | 492,529 | -19.2% | 0.04% | -23.1% |
Q3 2016 | $47,789,000 | +19.8% | 609,631 | +16.5% | 0.05% | +13.0% |
Q2 2016 | $39,886,000 | -33.3% | 523,505 | -17.0% | 0.05% | -28.1% |
Q1 2016 | $59,815,000 | -7.4% | 630,568 | -9.4% | 0.06% | -16.9% |
Q4 2015 | $64,612,000 | -20.0% | 695,649 | -26.6% | 0.08% | -31.2% |
Q3 2015 | $80,784,000 | -56.1% | 948,045 | -55.9% | 0.11% | -47.9% |
Q2 2015 | $183,839,000 | +13.7% | 2,147,887 | +12.8% | 0.22% | +15.0% |
Q1 2015 | $161,724,000 | +150.6% | 1,904,864 | +153.0% | 0.19% | +156.2% |
Q4 2014 | $64,535,000 | +2.9% | 752,945 | -8.7% | 0.07% | +2.8% |
Q3 2014 | $62,691,000 | -8.4% | 825,081 | -5.1% | 0.07% | -6.6% |
Q2 2014 | $68,426,000 | +98.0% | 869,119 | +88.6% | 0.08% | +68.9% |
Q1 2014 | $34,560,000 | -46.8% | 460,809 | -45.2% | 0.04% | -49.4% |
Q4 2013 | $64,951,000 | +303.9% | 841,319 | +262.7% | 0.09% | +256.0% |
Q3 2013 | $16,080,000 | +0.7% | 231,979 | -8.1% | 0.02% | -13.8% |
Q2 2013 | $15,972,000 | – | 252,305 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |